Kenneth Hawkins
Family · Senatobia, MSNPI 1730692914
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,818 of the $13,301 with a category attached, or 73.8%. 41 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 32.1% of the total. Reporting peaked in 2024 at $4,943 and has fallen 86.0% since, to $693 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $37.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
- AbbVie$2K
- Novo Nordisk$967
- AstraZeneca$580
- Boehringer Ingelheim$513
- GSK$488
- plus $5K from 35 others
What the payments were for
- Consulting fees$2,50019%
- Travel & lodging$9837%
- Food & beverage$9,81874%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,301 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 71 | $94,729 |
| FarxigaDapagliflozin Propanediol | 69 | $77,443 |
| OzempicSemaglutide | 63 | $71,640 |
| JardianceEmpagliflozin | 47 | $65,652 |
| XareltoRivaroxaban | 50 | $58,537 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $58,312 |
| EliquisApixaban | 53 | $57,012 |
| TrulicityDulaglutide | 19 | $42,500 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $37,461 |
| LinzessLinaclotide | 33 | $37,346 |
| JanuviaSitagliptin Phosphate | 26 | $28,787 |
| Nurtec OdtRimegepant Sulfate | 12 | $24,839 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $24,130 |
| UbrelvyUbrogepant | 15 | $23,306 |
| EntrestoSacubitril/Valsartan | 17 | $21,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $443 | $137,22990 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $513 | $104,26190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $580 | $90,378101 claims |
| PfizerEliquis, Nurtec Odt | $155 | $81,85165 claims |
| Novo NordiskOzempic, Novolog | $967 | $73,21574 claims |
| AbbVieLinzess, Ubrelvy | $1,884 | $60,65248 claims |
| Johnson & JohnsonXarelto | $234 | $58,53750 claims |
| GSKTrelegy Ellipta | $488 | $58,31242 claims |
| MerckJanuvia | $38 | $28,78726 claims |
| NovartisEntresto | $29 | $21,87517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Senatobia
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.